The effectiveness of Genentech and Roche’s (RHHBY.OB) glioblastoma multiforme (GBM) treatment, Avastin, has recently been challenged raising concerns from physicians and patients alike that a huge void in patient care can develop if the FDA decides to revoke Avastin’s approval for treating GBM.
Vancouver-based DelMar Pharmaceuticals [DMPI] is developing new drug candidates targeting orphan cancer indications representing market opportunities in the $100s of millions in North America and potentially billions of dollars worldwide. Promising data announced in 2012 with follow ups scheduled at various healthcare conferences this year coincided with the company’s recent listing on the OTCQB, which commenced Q1-2013. OneMedRadio spoke with the Del Mar CEO about these milestones.
DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.
Parting is such sweet sorrow when building a company from infancy and then letting go to see it spread its wings. Planning a proper exit strategy is crucial and not just when referring to love and war.
Del Mar Pharmaceuticals was recently added to the roster of presenting companies at OneMedForum NY 2011.
Copyright © 2024 | WordPress Theme by MH Themes